Preview

Современная ревматология

Расширенный поиск

Гигантоклеточный артериит. Часть II. Лечение

https://doi.org/10.14412/1996-7012-2012-762

Полный текст:

Аннотация

Рассматриваются варианты лечения гигантоклеточного артериита (ГКА) и его осложнений. ГКА поддается терапии ГК. Данные литературы свидетельствуют о необходимости госпитализации больных ГКА с острой потерей зрения или ишемией мозга для внутривенного введения мегадоз метилпреднизолона, а также контроля и предупреждения осложнений терапии ГК. В этих случаях целесообразно назначение аспирина. Обсуждаются доказательства применения в качестве ГК-сберегающих агентов метотрексата, а также других базисных противовоспалительных и генно-инженерных биологических препаратов.

Литература

1. <div><p>Fraser J.A., Weyand C.M., Newman N.J. et al. The Treatment of Giant Cell Arteritis. Rev Neurol Dis 2008; 5(3): 140—52.</p><p>Salvarani C., Cantini F., Bolardi L. et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261 —71.</p><p>Rahman W., Rahman F.Z. Major review Р giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol 2005; 50: 415—28.</p><p>Hayreh S.S., Zimmerman В. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica 2003; 217: 239—59.</p><p>Pipitone N., Boiardi L., Salvarini C. Are steroids alone sufficient for the treatment of giant cell arteritis? Best Pract Res Clin Rheum 2005; 19: 277—92.</p><p>Lundberg I., Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatic and temporal arteritis. J Rheum 1990; 17: 1340—5.</p><p>Weyand C.M., Goronzy J.J. Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 160—9.</p><p>Chevalet P., Barrier J.H., Pottier P. et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients. J Rheum 2000; 27: 1484—91.</p><p>Mazlumzadeh M., Hunder G.G., Easley K.A. et al. Treatment of giant cell arteritis using induction therapy with highdose corticosteroids: a double-blind, placebocontrolled, randomized prospective clinical trial. Arthr Rheum 2006; 54: 3310—8.</p><p>Chan C.C.K., Paine M., O’Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001; 85: 1061—4.</p><p>Hayreh S.S., Zimmerman В., Kardon R.H. Visual improvement with corticosteroid therapy in giant cell arteritis: report of a large study and review of the literature. Acta Ophthalmol Scand 2002; 80: 353—67.</p><p>Foroozan R., Deramo V.A., Buono L.M. et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003; 110: 539—42.</p><p>Danesh-Meyer H., Savino P.J., Gamble G.G. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005; 112: 1098—103.</p><p>Eberhardt R.T., Dhadly M. Giant cell arteritis: diagnosis, management, and cardiovascular implications. Cardiol Rev 2007; 15: 55—61.</p><p>Cornblath W.T., Eggenberger E.R. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 1997; 104: 854—8.</p><p>Loddenkemper T., Sharma P., Katzan I. et al. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry 2007; 78: 1255—9.</p><p>Gonzales-Gay M.A., Blanco R., Rodriguez-Valverde V. et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthr Rheum1998; 41: 1497—504.</p><p>Hayreh S.S., Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003; 110: 1204—15.</p><p>Rucker J.C., Biousse V., Newman N.J. Ischemic optic neuropathies. Curr Opin Neurol 2004; 17: 27—35.</p><p>Hunder G.G., Sheps S.G., Allen G.L. et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Int Med 1975; 82: 613—8.</p><p>Weyand C.M., Fulbright J.W., Hunder G.G. et al. Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity. Arthr Rheum 2000; 43: 1041—8.</p><p>Wilke W.S., Hoffman G.S. Treatment of corticosteroid-resistant giant cell arteritis. Rheum Dis Clin North Am 1995; 21: 59—71.</p><p>Spiera R.F., Mitnick H.J., Kupersmith M. et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheum 2001; 19: 495—501.</p><p>Hoffman G.S., Cid M.C., Hellmann D.B. et al. for the International Network for the Study of Systemic Vasculitides (INSSYS) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthr Rheum 2002; 46: 1309—18.</p><p>Jover J.A., Hernandez-Garcia C., Morado I.C. et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Int Med 2001; 134: 106—14.</p><p>Mahr A.D., Jover J.A., Spiera R.D. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthr Rheum 2007; 56: 2789—97.</p><p>Hoffman G.S., Cid M.C., Rendt-Zagar K.E. et al. Infliximab for maintenance of glucocorticoid-induced remission of giant cell arteritis. Ann Int Med 2007; 146: 621 —30.</p><p>Martinez-Taboada V.M., Rodriguez-Valverde V., Carreno L. et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67: 625—30.</p><p>De Silva M., Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136—8.</p><p>Schaufelberger C., Hollby H., Bratt J. et al. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheum 2006; 35: 327—9.</p><p>Field M., Cook A., Gallagher G. Immunolocalisation of tumour necrosis factor and its receptors in temporal arteritis. Rheum Int 1997; 17: 113—8.</p><p>Cantini F., Niccoli L., Savarani C. et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthr Rheum 2001; 44: 2933—5.</p><p>Uthman I., Kanj N., Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheum 2006; 25: 109—10.</p><p>Nuenninghoff D.M., Matteson E.L. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheum 2003; 21(6 Suppl 2): S29—34.</p><p>Liozon F., Vidal E., Barrier J. Does dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity? Clin Exp Rheum 1993; 11: 694—5.</p><p>Nesher G., Sonnenblick M. Steroid-sparing medications in temporal arteritis: report of three cases and review of 174 reported patients. Clin Rheum 1994; 13: 289—92.</p><p>Doury P., Pattin S., Eulry F. et al. The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthr Rheum 1983; 26: 689—90.</p><p>De Vita S., Tavoni A., Jeracitano G. et al. Treatment of giant cell arteritis with cyclophosphamide pulses. J Int Med 1992; 232: 373—5.</p><p>Ahmed M.M., Mubashir E., Hayat S. et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheum 2007; 26: 1353—5.</p><p>Leydet-Quilici H., Luc M., Armingeat T. et al. Giant cell arteritis during adalimumab treatment for rheumatoid arthritis. J Bone Spine 2007; 74: 299—305.</p><p>Bhatia A., Ell P.J., Edwards J.C.W. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005; 64: 1099—100.</p><p>Mukhtyar C., Guilevin L., Cid M.C. et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 3: 318—23.</p><p>Баранов А.А. Рекомендации по ведению больных васкулитами (по материалам рекомендаций европейской антиревматической лиги). Совр. ревматол. 2009; 2: 5-9.</p><p>Национальное руководство по ревматологии. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 565—7.</p><p>Seitz M., Reichenbach S., Bonel H.M. et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141: w13156.</p><p>Vinit J., Bielefeld P., Muller G. et al. Efficacy of tocilizumab in refractory giant cell arteritis. J Bone Spine 2012 [Epub ahead of print].</p><p>Catanoso M., Pipitone N., Magnani L. et al. New indications for biological therapies. Int Emerg Med 2011; 6(Suppl 1): 1—9.</p></div><br />


Для цитирования:


Сатыбалдыев А.М. Гигантоклеточный артериит. Часть II. Лечение. Современная ревматология. 2012;6(4):49-54. https://doi.org/10.14412/1996-7012-2012-762

For citation:


Satybaldyev A.M. Giant cell arteritis. Part II. Treatment. Modern Rheumatology Journal. 2012;6(4):49-54. (In Russ.) https://doi.org/10.14412/1996-7012-2012-762

Просмотров: 692


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)